Suvorexant (Belsomra) and Ketamine Therapy | Tovani Health
Belsomra (Suvorexant) — Dual orexin receptor antagonist (DORA, sleep aid)
Verdict at Tovani Health
Compatible; the next-morning residual sedation can stack with a morning session.
Suvorexant and ketamine are compatible. The thing to plan around: suvorexant can produce next-morning sedation more reliably than Z-drugs or melatonin. Morning sessions on the day after a dose may overlap with residual effect.
If you take Belsomra regularly and are considering at-home ketamine therapy, the combination is safe with monitoring or dose adjustment. This page covers the brief pharmacologic context and what we do at intake.
How Belsomra interacts with ketamine
Suvorexant blocks orexin receptors, the wakefulness-promoting peptide system. The half-life (about 12 hours) produces measurable residual effect into the next day for many patients.
What we do at intake
Tell us the dose and time you typically take it. We may shift sessions to the afternoon if morning sedation is significant.
Bottom line
Suvorexant and ketamine are compatible. The thing to plan around: suvorexant can produce next-morning sedation more reliably than Z-drugs or melatonin. Morning sessions on the day after a dose may overlap with residual effect.
Frequently Asked Questions
Is Belsomra safer than Ambien for KAP?
Different profile. Belsomra has more next-day residual; Ambien has more abuse potential and sleep-walking risk. Both are workable.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Belsomra (Suvorexant) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI.. Clinical Pharmacokinetics. 2016. PMID: 27028535
Comprehensive clinical pharmacokinetics/pharmacodynamics review of ketamine including CYP-mediated drug interactions (CYP3A4, CYP2B6).
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 16, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.